← Back to All US Stocks

Weed, Inc.. (BUDZ) Stock Fundamental Analysis & AI Rating 2026

BUDZ OTC Services-Commercial Physical & Biological Research NV CIK: 0001393772
Updated This Month • Analysis: Mar 21, 2026 • SEC Data: 2025-06-30
Combined AI Rating
STRONG SELL
94% Confidence
STRONG AGREEMENT
STRONG SELL
95% Conf
STRONG SELL
94% Conf

📊 BUDZ Key Takeaways

Revenue: $0.0
Net Margin: N/A
Free Cash Flow: $-70.5K
Current Ratio: 0.02x
Debt/Equity: N/A
EPS: $0.00
AI Rating: STRONG SELL with 95% confidence
Weed, Inc.. (BUDZ) receives a STRONG SELL rating with 94% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $0, Weed, Inc.. demonstrates mixed fundamentals in the Healthcare sector. Below is our complete BUDZ stock analysis for 2026.

Is Weed, Inc.. (BUDZ) a Good Investment?

Claude

WEED, INC. exhibits severe financial distress with zero revenue, negative stockholders equity of -$447.9K, and deteriorating cash burn of -$70.5K in operating cash flow. The company is technically insolvent with liabilities exceeding assets by $447.9K, leaving no margin for error and indicating critical viability concerns.

ChatGPT

The fundamentals are extremely weak: the company reported zero revenue, ongoing operating losses, negative operating and free cash flow, and a deeply stressed balance sheet. Negative equity, minimal cash, and a current ratio of 0.02x indicate severe financial fragility, while the absence of revenue suggests there is no evidence of sustainable operating traction.

Why Buy Weed, Inc.. Stock? BUDZ Key Strengths

Claude
  • + Minimal capital expenditure requirements suggests asset-light business model
  • + Some insider activity indicates management awareness and potential engagement
  • + Classification in research services sector allows for potential pivot or licensing opportunities
ChatGPT
  • + Reported net loss is relatively small versus operating loss, which may reflect limited non-operating burden in the latest period
  • + No capital expenditure requirements in the latest period may reduce near-term cash demands
  • + Asset base is still positive, providing at least some residual operating foundation

BUDZ Stock Risks: Weed, Inc.. Investment Risks

Claude
  • ! Zero revenue generation with no clear path to commercialization
  • ! Negative stockholders equity represents technical insolvency and existential solvency risk
  • ! Severe liquidity crisis with current ratio of 0.02x and only $5.3K cash against $996.8K liabilities
  • ! Ongoing negative cash burn of -$70.5K with minimal liquidity runway of less than 1 month
  • ! Operating losses of -$528.8K indicate non-viable core business operations
ChatGPT
  • ! Zero revenue indicates no demonstrated business scale or earnings power
  • ! Negative stockholders equity and total liabilities exceeding assets signal balance-sheet distress
  • ! Very low cash balance and negative operating cash flow raise substantial liquidity and going-concern risk

Key Metrics to Watch

Claude
  • * Revenue generation and path to positive cash flow
  • * Stockholders equity trajectory and recapitalization efforts
  • * Cash burn rate and remaining liquidity runway
  • * Debt restructuring or capital raise announcements
ChatGPT
  • * Revenue generation and consistency of any top-line growth
  • * Cash balance, operating cash burn, and improvement in working capital / current ratio

Weed, Inc.. (BUDZ) Financial Metrics & Key Ratios

Revenue
$0.0
Net Income
$-107.6K
EPS (Diluted)
$0.00
Free Cash Flow
$-70.5K
Total Assets
$548.9K
Cash Position
$5.4K

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

BUDZ Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA -19.6%
FCF Margin N/A

BUDZ vs Healthcare Sector: How Weed, Inc.. Compares

How Weed, Inc.. compares to Healthcare sector averages

Net Margin
BUDZ 0.0%
vs
Sector Avg 12.0%
BUDZ Sector
ROE
BUDZ 0.0%
vs
Sector Avg 15.0%
BUDZ Sector
Current Ratio
BUDZ 0.0x
vs
Sector Avg 2.0x
BUDZ Sector
Debt/Equity
BUDZ 0.0x
vs
Sector Avg 0.6x
BUDZ Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Weed, Inc.. Stock Overvalued? BUDZ Valuation Analysis 2026

Based on fundamental analysis, Weed, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
N/A
Sector avg: 15%
Net Profit Margin
N/A
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
N/A
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Weed, Inc.. Balance Sheet: BUDZ Debt, Cash & Liquidity

Current Ratio
0.02x
Quick Ratio
-0.05x
Debt/Equity
N/A
Debt/Assets
181.6%
Interest Coverage
-104.30x
Long-term Debt
N/A

BUDZ Revenue & Earnings Growth: 5-Year Financial Trend

BUDZ 5-year financial data: Year 2018: Revenue $0, Net Income N/A, EPS N/A. Year 2019: Revenue $0, Net Income N/A, EPS N/A. Year 2020: Revenue $0, Net Income -$27.5M, EPS N/A. Year 2023: Revenue $0, Net Income N/A, EPS N/A. Year 2025: Revenue $0, Net Income -$510.7K, EPS $0.00.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Weed, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $0.00 indicates the company is currently unprofitable.

BUDZ Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

BUDZ Quarterly Earnings & Performance

Quarterly financial performance data for Weed, Inc.. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q2 2025 N/A -$95.9K $0.00
Q1 2025 N/A -$95.9K $0.00
Q3 2024 N/A -$95.9K N/A
Q2 2024 N/A -$111.0K N/A
Q1 2024 N/A -$31.6K N/A
Q3 2021 N/A -$173.3K N/A
Q1 2021 N/A -$971.7K N/A
Q3 2020 N/A -$176.6K N/A

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

Weed, Inc.. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$70.5K
Cash generated from operations
Dividends
None
No dividend program

BUDZ SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Weed, Inc.. (CIK: 0001393772)

📋 Recent SEC Filings

Date Form Document Action
Apr 8, 2026 10-K budz_10k.htm View →
Feb 24, 2026 4 xslF345X05/form4.xml View →
Dec 29, 2025 10-Q/A budz_10qa.htm View →
Dec 23, 2025 10-Q budz_10q.htm View →
Aug 14, 2025 10-Q budz_10q.htm View →

Frequently Asked Questions about BUDZ

What is the AI rating for BUDZ?

Weed, Inc.. (BUDZ) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.

What are BUDZ's key strengths?

Claude: Minimal capital expenditure requirements suggests asset-light business model. Some insider activity indicates management awareness and potential engagement. ChatGPT: Reported net loss is relatively small versus operating loss, which may reflect limited non-operating burden in the latest period. No capital expenditure requirements in the latest period may reduce near-term cash demands.

What are the risks of investing in BUDZ?

Claude: Zero revenue generation with no clear path to commercialization. Negative stockholders equity represents technical insolvency and existential solvency risk. ChatGPT: Zero revenue indicates no demonstrated business scale or earnings power. Negative stockholders equity and total liabilities exceeding assets signal balance-sheet distress.

What is BUDZ's revenue and growth?

Weed, Inc.. reported revenue of $0.0.

Does BUDZ pay dividends?

Weed, Inc.. does not currently pay dividends.

Where can I find BUDZ SEC filings?

Official SEC filings for Weed, Inc.. (CIK: 0001393772) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is BUDZ's EPS?

Weed, Inc.. has a diluted EPS of $0.00.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is BUDZ a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, Weed, Inc.. has a STRONG SELL rating with 94% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is BUDZ stock overvalued or undervalued?

Valuation metrics for BUDZ: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy BUDZ stock in 2026?

Our dual AI analysis gives Weed, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is BUDZ's free cash flow?

Weed, Inc..'s operating cash flow is $-70.5K, with capital expenditures of $0.0.

How does BUDZ compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.02 (avg: 2).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 21, 2026 | Data as of: 2025-06-30 | Powered by Claude AI